|
Evaluating oncologists’ practice patterns and decision-making in locally advanced or metastatic urothelial carcinoma (la/mUC): The U.S. physician PARADIGM study (Part 2). |
| |
|
|
Stock and Other Ownership Interests - EMD Serono; Merck |
Research Funding - EMD Serono |
Travel, Accommodations, Expenses - EMD Serono |
| |
|
Employment - Kantar Health |
Consulting or Advisory Role - EMD Serono (Inst) |
Research Funding - EMD Serono (Inst) |
| |
|
Employment - EMD Serono; Seagen |
Stock and Other Ownership Interests - Seagen |
| |
|
Employment - Kantar Health |
Consulting or Advisory Role - EMD Serono (Inst) |
Research Funding - EMD Serono (Inst) |
| |
|
|
Stock and Other Ownership Interests - EMD Serono |
Research Funding - EMD Serono |
Travel, Accommodations, Expenses - EMD Serono |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Moderna Therapeutics; Nektar |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - AVEO; EMD Serono; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Pfizer |
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology |